<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00660062</url>
  </required_header>
  <id_info>
    <org_study_id>DUAG-7</org_study_id>
    <nct_id>NCT00660062</nct_id>
  </id_info>
  <brief_title>Relapse Prevention With Escitalopram or Nortriptyline Following Electro-Convulsive Treatment (DUAG-7)</brief_title>
  <acronym>DUAG-7</acronym>
  <official_title>Relapse Prevention in Patients With a Major Depressive Episode Treated With Electroconvulsive Treatment Using a Fixed Dose Range of Escitalopram Compared to a Fixed Dose of Nortriptyline (DUAG-7) A Randomised Controlled 6 Month Double-blind Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hillerod Hospital, Denmark</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hillerod Hospital, Denmark</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to investigate the relapse preventing efficacy of
      escitalopram in a dose range and nortriptylin in a single dose in patients having been
      treated successfully with a course of electroconvulsive treatment (ECT).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study records severity of depression and relapse in patients treated for a major
      depressive disorder with electroconvulsive treatment (ECT)in a period og 6 month after end of
      ECT treatment. Patients will be randomized into four groups treated with escitalopram 10 mg,
      20 mg, 30 mg or nortriptylin 100 mg daily dosages. The primary outcome measure is relapse and
      secondary outcome measure is tolerability.

      The study is a multicenter trial within Denmark.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Slow inclusion
  </why_stopped>
  <start_date>August 2009</start_date>
  <completion_date type="Actual">November 2014</completion_date>
  <primary_completion_date type="Actual">November 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hamilton depression rating scale</measure>
    <time_frame>14 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Drop out due to side-effects of drugs</measure>
    <time_frame>14 days</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">47</enrollment>
  <condition>Major Depression</condition>
  <arm_group>
    <arm_group_label>Escitalopram 10 mg daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Escitalopram 10 mg daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Escitalopram 20 mg daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Escitalopram 20 mg daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>escitalopram 30 mg daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>escitalopram 30 mg daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nortriptylin 100 mg daily</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Nortriptylin 100 mg daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>escitalopram</intervention_name>
    <description>10 mg daily</description>
    <arm_group_label>Escitalopram 10 mg daily</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>escitalopram</intervention_name>
    <description>20 mg daily dosage</description>
    <arm_group_label>Escitalopram 20 mg daily</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>escitalopram</intervention_name>
    <description>30 mg daily dosage</description>
    <arm_group_label>escitalopram 30 mg daily</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nortriptyline</intervention_name>
    <description>100 mg daily dosage</description>
    <arm_group_label>Nortriptylin 100 mg daily</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Remission from a major depressive episode after ECT treatment

        Exclusion Criteria:

          -  Suicidality (Hamilton item 3 score of 3 or more)

          -  Symptoms mania (MAS score of 15 or more)

          -  Duration of actual depressive episode more than 2 years

          -  Compulsory measures of any kind

          -  Dementia

          -  Severe somatic illness

          -  Pregnant or lactating subject

          -  Known clinical relevant malabsorption.

          -  Epilepsia

          -  Clinically substantial cognitive deterioration due to ECT treatment

          -  schizophrenia, schizopreniform or schizo-affective disorder

          -  Bipolar I, Bipolar II eller

          -  Rapid cycling bipolar disorder

          -  Abuse of alcohol or drugs

          -  Early relapse (less than 2 month) after ECT

          -  Inadequate contraception

          -  Known intolerance to any of the used study medications

          -  Myocardial infarction in the last 6 month

          -  Clinical important liver disease

          -  Any known disturbance of the cardiac conduction system, cardiac insufficiency,or other
             clinical important cardiac disease

          -  Treatment with a MAO-inhibitor

          -  Treatment with norepinephrine or epinephrine

          -  Known hyperthyroidism or treatment with thyroid hormones

          -  Known ortostatic hypertension.

          -  Glaucoma

          -  Known hereditary galactoseintolerance, Lapp Lactase deficiency) or
             gluco-se/galactosemalabsorption.

          -  Ongoing treatment with sympatomimetica efedrine, isoprenaline, physostigmine,
             dopamine, levodopa, phenylephrine.

          -  Ongoing treatment with anticholinergica, antiparkinson treatment, antihistamines,
             atropine, biperiden,

          -  Ongoing treatment with drugs that prolongs the cardiac QT-interval, such as quinidine,
             antihistamines, terfenadine og sotalole

          -  Ongoing treatment with fluconazole or terbinafine

          -  Ongoing treatment with mefloquin.

          -  Known intolerance to escitalopram

          -  Ongoing treatment with serotonergic acting substances such as tramadole, sumatriptane
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Klaus Martiny, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mental Health Center Copenhagen Department O</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mental Health Centre Copenhagen Department O</name>
      <address>
        <city>Copenhagenl</city>
        <zip>2100 Ã˜</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <link>
    <url>http://www.duag.dk</url>
    <description>homepage for the DUAG organization</description>
  </link>
  <reference>
    <citation>Sackeim HA, Haskett RF, Mulsant BH, Thase ME, Mann JJ, Pettinati HM, Greenberg RM, Crowe RR, Cooper TB, Prudic J. Continuation pharmacotherapy in the prevention of relapse following electroconvulsive therapy: a randomized controlled trial. JAMA. 2001 Mar 14;285(10):1299-307.</citation>
    <PMID>11255384</PMID>
  </reference>
  <verification_date>April 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 14, 2008</study_first_submitted>
  <study_first_submitted_qc>April 16, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 17, 2008</study_first_posted>
  <last_update_submitted>December 7, 2014</last_update_submitted>
  <last_update_submitted_qc>December 7, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 9, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hillerod Hospital, Denmark</investigator_affiliation>
    <investigator_full_name>Klaus Martiny</investigator_full_name>
    <investigator_title>Senior Consultant</investigator_title>
  </responsible_party>
  <keyword>Major depression</keyword>
  <keyword>relapse prevention</keyword>
  <keyword>ECT</keyword>
  <keyword>escitalopram</keyword>
  <keyword>nortriptyline</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Recurrence</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Citalopram</mesh_term>
    <mesh_term>Nortriptyline</mesh_term>
    <mesh_term>Dexetimide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

